AI Terminal
Vimian Group AB
Delisting Announcement • Mar 28, 2025
8618_rns_2025-03-28_c6e61d0b-4e1a-4341-bb6c-122665fe4d72.pdf
Delisting Announcement
Open in ViewerOpens in native device viewer
Press Release 28 March 2025 07:30:00 CET
Trading in Vimian Group AB (publ)'s ordinary shares on Nasdaq Stockholm commences today
Vimian Group AB (publ) announces today the commencement of trading in the company's ordinary shares on Nasdaq Stockholm.
"Today marks an important milestone for Vimian as we start trading on Nasdaq's Main Market. Vimian has a history of delivering strong and profitable growth and is today a leader in select niches of the global animal health market. We continue to see significant potential ahead of us and are well positioned to accelerate value creation for our customers and shareholders around the world", says Patrik Eriksson, CEO of Vimian Group.
Vimian's ordinary shares will be traded in the Large Cap segment with unchanged ticker (VIMIAN) and unchanged ISIN code (SE0015961982). There will be no offer or issuance of new shares in connection with the change of marketplace to Nasdaq Stockholm and shareholders in Vimian do not need to take any action in connection therewith.
Advokatfirman Vinge is acting as legal advisor to Vimian in connection with the listing on Nasdaq Stockholm.
For further information, please contact:
Maria Dahllöf Tullberg
Head of IR, Communications & Sustainability [email protected] +46 736 26 88 86
About Vimian
Vimian is a global animal health company covering four essential and rapidly evolving areas: Specialty Pharma, MedTech, Veterinary Services and Diagnostics. At Vimian, we believe that every animal deserves the best available care. We bring pioneering and entrepreneurial businesses together to make the market's most innovative offerings accessible to more animal health professionals and pet owners. Headquartered in Stockholm, Sweden, Vimian reaches over 17,000 veterinary clinics and laboratories, sells to over 80 markets, has 1,200 employees and annual revenues of approximately EUR 375 million. For more information, please visit: www.vimian.com.
Attachments
Trading in Vimian Group AB (publ)'s ordinary shares on Nasdaq Stockholm commences today